Publicaciones (42) Publicaciones en las que ha participado algún/a investigador/a

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544

  4. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

    Breast Cancer Research and Treatment, Vol. 165, Núm. 3, pp. 601-609

  5. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment

    Oncogene, Vol. 36, Núm. 41, pp. 5695-5708

  6. Advances in interventionist techniques to increase safety

    Revista de la Sociedad Espanola del Dolor, Vol. 24

  7. Advances in interventionist techniques to increase safety

    Revista de la Sociedad Espanola del Dolor, Vol. 24, Núm. 5, pp. 264-268

  8. Advances in the management of HER2-positive early breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 119, pp. 113-122

  9. Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: A pilot study in asymptomatic women

    BMC Women's Health, Vol. 17, Núm. 1

  10. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 7, pp. 904-916

  11. Calidad de vida percibida en el programa municipal comunitario de promoción de la salud «Gente saludable». Ciudad Lineal-Madrid

    Semergen: revista española de medicina de familia, Núm. 5, pp. 358-363

  12. Colonic endoscopic full-thickness resection (EFTR) with the over-the-scope device (FTRD): a short case series

    Revista Española de Enfermedades Digestivas, Vol. 109, Núm. 3, pp. 230-233

  13. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

  14. Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition after Myocardial Infarction

    Circulation Research, Vol. 121, Núm. 4, pp. 439-450

  15. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

  16. El volumen extracelular no se asocia a arritmias malignas en miocardiopatía hipertrófica de alto riesgo

    Revista Espanola de Cardiologia, Vol. 70, Núm. 11, pp. 933-940

  17. Eruptive keratoacanthomas associated with pembrolizumab therapy

    JAMA Dermatology, Vol. 153, Núm. 7, pp. 694-697

  18. Evolution of energy related metabolites in plasma from newborns with hypoxic-ischemic encephalopathy during hypothermia treatment

    Scientific Reports, Vol. 7, Núm. 1

  19. Exanthema, fever and arthralgia in a pregnant woman

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 6, pp. 384-385

  20. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 4, pp. 545-554